Boryung Pharmaceutical
As of the edition of 20 October 2026, Boryung Pharmaceutical runs 62 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Boryung Pharmaceutical was renamed in 2022.
- Boryung Pharmaceutical Co., Ltd: renamed in 2022
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 18 |
| Went quiet | 10 |
| Stopped | 1 |
| Status not established | 31 |
| Total | 62 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lafutidine | none listed | 1 |
| Cilnidipine | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Heart and blood vessels: 59 trials led
- Nutrition and metabolism: 19 trials led
- Hormones: 11 trials led